Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 2128

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 16
Chunk 2128
---

    Year Ended  
    Year Ended 

    December 31,  2024  
    December 31, 2023 

    Formation and operating costs 
    $1,649,106  
    $3,173,826 
  
    Loss from operations 
     1,649,106  
     3,173,826 

    Other expense/(income) 

    Interest expense 
     96,242  
     36,909 
  
    Income on Trust account 
     (1,578,042) 
     (3,843,271)

    Net (loss)/ income 
    $(167,306) 
    $632,536 

    Basic and diluted weighted average redeemable ordinary shares outstanding 
     2,722,627  
     7,416,033 
  
    Basic and diluted net income per redeemable ordinary shares 
    $0.32  
    $0.26 

    Basic and diluted weighted average non-redeemable ordinary shares outstanding 
     2,572,500  
     2,572,500 
  
    Basic and diluted net loss (income) per non-redeemable ordinary share 
    $(0.40) 
    $(0.50)

The
accompanying notes are an integral part of these consolidated financial statements.

F-5

DENALI
CAPITAL ACQUISITION CORP.

CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

    For
    the Year Ended December 31, 2024 

    Class
    A Ordinary Shares  
    Class
    B Ordinary Shares  
    Accumulated  
    Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Deficit  
    Equity
    Deficit 
  
    Balance
    as of December 31, 2023 
     510,000  
    $    51  
    $2,062,500  
    $206  
    $(8,282,297) 
    $      (8,282,040)
  
    Net
    loss 
     -  
     -  
     -  
     -  
     (167,306)  
     (167,306) 
  
    Subsequent
    measurement of